Journal of Clinical Oncology

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis

Specification Sheet

Guardant360^® CDx provides guideline-recommended genomic results in 7 days from a routine blood draw, eliminating the need to solely rely on tissue testing.